Abstract
KCa3.1 protein is part of a heterotetrameric voltage-independent potassium channel, the activity of which depends on the intracellular calcium binding to calmodulin. KCa3.1 is immensely significant in regulating immune responses and primarily expressed in cells of hematopoietic lineage. It is one of the attractive pharmacological targets that are known to inhibit neuroinflammation. KCa3.1 blockers mediate neuroprotection through multiple mechanisms, such as by targeting microglia-mediated neuronal killing. KCa3.1 modulators may provide alternative treatment options for neurological disorders like ischemic stroke, Alzheimer disease, glioblastoma multiforme, multiple sclerosis and spinal cord injury. This review is an attempt to draw attention towards KCa3.1 channel, which was never exploited to its full potential as a viable therapeutic candidate against various neurological disorders.
Keywords: Alzheimer disease, glioblastoma multiforme, ischemic stroke, KCa3.1, KCNN4, multiple sclerosis.
CNS & Neurological Disorders - Drug Targets
Title:Role of KCa3.1 Channels in CNS Diseases: A Concise Review
Volume: 15 Issue: 10
Author(s): Sinoy Sugunan, Sreekala S. Nampoothiri, Tanya Garg and Rajanikant G. Krishnamurthy
Affiliation:
Keywords: Alzheimer disease, glioblastoma multiforme, ischemic stroke, KCa3.1, KCNN4, multiple sclerosis.
Abstract: KCa3.1 protein is part of a heterotetrameric voltage-independent potassium channel, the activity of which depends on the intracellular calcium binding to calmodulin. KCa3.1 is immensely significant in regulating immune responses and primarily expressed in cells of hematopoietic lineage. It is one of the attractive pharmacological targets that are known to inhibit neuroinflammation. KCa3.1 blockers mediate neuroprotection through multiple mechanisms, such as by targeting microglia-mediated neuronal killing. KCa3.1 modulators may provide alternative treatment options for neurological disorders like ischemic stroke, Alzheimer disease, glioblastoma multiforme, multiple sclerosis and spinal cord injury. This review is an attempt to draw attention towards KCa3.1 channel, which was never exploited to its full potential as a viable therapeutic candidate against various neurological disorders.
Export Options
About this article
Cite this article as:
Sugunan Sinoy, Nampoothiri S. Sreekala, Garg Tanya and Krishnamurthy G. Rajanikant, Role of KCa3.1 Channels in CNS Diseases: A Concise Review, CNS & Neurological Disorders - Drug Targets 2016; 15 (10) . https://dx.doi.org/10.2174/1871527315666160822111913
DOI https://dx.doi.org/10.2174/1871527315666160822111913 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mast Cells: Target and Source of Neuropeptides
Current Pharmaceutical Design Alcohol Enhances HIV Infection of Cord Blood Monocyte-Derived Macrophages
Current HIV Research Investigating the In Vivo Expression Patterns of miR-7 microRNA Family Members in the Adult Mouse Brain
MicroRNA Preface: Scope of Current Alzheimer Research Debomoy
Current Alzheimer Research Neurophysiological Mechanisms Related to Pain Management in Bone Tumors
Current Neuropharmacology Racial Differences in Gray Matter Integrity by Diffusion Tensor in Black and White Octogenarians
Current Alzheimer Research Ghrelin, A Novel Peptide Hormone in the Regulation of Energy Balance and Cardiovascular Function
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Toward The Rational Design of Cell Fate Modifiers Notch Signaling as a Target for Novel Biopharmaceuticals
Current Pharmaceutical Biotechnology Mephedrone Impact on Matrix Metalloproteinases Activity - Do they Influence the Memory Processes?
Current Molecular Pharmacology Editorial [ Pain Guest Editors: Robert W. Gereau IV & Ferdinando Nicoletti ]
Current Neuropharmacology Recent Patents Relating to siRNAs and Therapeutic Strategies for Genetic Diseases
Recent Patents on DNA & Gene Sequences Basic Sleep Mechanisms: An Integrative Review
Central Nervous System Agents in Medicinal Chemistry Recent Advances in Protein−Ligand Interactions: Molecular Dynamics Simulations and Binding Free Energy
Current Computer-Aided Drug Design Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges
Cardiovascular & Hematological Agents in Medicinal Chemistry Novel Anti-arrhythmic Medications in the Treatment of Atrial Fibrillation
Current Cardiology Reviews Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery Epidemiological and Clinical Data of Amniotic Fluid Embolism in Forensic Settings
Current Pharmaceutical Biotechnology The Use of Microarrays to Characterize Neuropsychiatric Disorders: Postmortem Studies of Substance Abuse and Schizophrenia
Current Molecular Medicine Astrocytes Exert and Control Immune Responses in the Brain
Current Immunology Reviews (Discontinued) Suicide Risk in Obsessive-Compulsive Disorder and Exploration of Risk Factors: A Systematic Review
Current Neuropharmacology